Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA).
Nicholas J. Vogelzang
Consultant or Advisory Role - Bayer; Bayer
Research Funding - Bayer
Chris Parker
Consultant or Advisory Role - Algeta (U); Bayer
Sten Nilsson
Consultant or Advisory Role - Algeta
Jose Garcia-Vargas
Employment or Leadership Position - Bayer
Robert Edward Coleman
Honoraria - Amgen; Bayer
Expert Testimony - Novartis
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Minghua Shan
Employment or Leadership Position - Bayer
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer